An Ono Pharma drug for a type of tumor affecting tissues of the joints is now FDA approved, giving the Japanese company a product with dosing and safety advantages over the Daiichi Sankyo product that ...
Emactuzumab has received FDA fast track designation for TGCT treatment, aiding development for conditions lacking effective options. The phase 3 TANGENT trial evaluates emactuzumab, a CSF-1R ...
Macrophage colony-stimulating factor 1 receptor (CSF-1R) is a transmembrane tyrosine kinase receptor expressed in brain microglia, and mutations in the CSF1R gene have been linked to adult-onset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results